Keith Robison has a post on his Omics! Omics! blog about the toxicogenomics field and his take on the recent announcement that Entelos plans to acquire Iconix. Despite the appeal of killing off toxic compounds earlier in the discovery and development process, "toxicogenomics is an area which just hasn't panned out as a business model," Robison writes. "It may well be yet another area where Big Pharma doesn't really see the advantage of small biotech in doing it, or perhaps doesn't trust that work to outsiders."
Toxic Relationship with Toxicogenomics?
Sep 06, 2007
What's Popular?